Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 325

1.

What risk of death would people take to be cured of HIV and why? A survey of people living with HIV.

Murray BR, Kratka A, Scherr KA, Eyal N, Blumenthal-Barby J, Freedberg KA, Kuritzkes DR, Hammitt JK, Edifor R, Katz MN, Pollak KI, Zikmund-Fisher BJ, Halpern SD, Barks MC, Ubel PA.

J Virus Erad. 2019 Apr 1;5(2):109-115.

2.

Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor.

Asundi A, Robles Y, Starr T, Landay A, Kinslow J, Ladner J, White L, Plank RM, Melbourne K, Weisholtz D, Bennett M, Pan H, Stern E, Lin A, Kuritzkes DR, Lin NH.

J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):585-593. doi: 10.1097/QAI.0000000000002079.

PMID:
31045650
3.

DNA engineered micromotors powered by metal nanoparticles for motion based cellphone diagnostics.

Draz MS, Kochehbyoki KM, Vasan A, Battalapalli D, Sreeram A, Kanakasabapathy MK, Kallakuri S, Tsibris A, Kuritzkes DR, Shafiee H.

Nat Commun. 2018 Oct 16;9(1):4282. doi: 10.1038/s41467-018-06727-8.

4.

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ.

J Infect Dis. 2018 Nov 5;218(12):1954-1963. doi: 10.1093/infdis/jiy479.

PMID:
30085241
5.

HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers.

Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ.

J Clin Invest. 2018 Aug 31;128(9):4074-4085. doi: 10.1172/JCI120549. Epub 2018 Aug 20.

6.

NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation.

Hogan LE, Körner C, Hobbs K, Simoneau CR, Thanh C, Gibson EA, Palmer CD, Pandit A, Marty FM, Kuritzkes DR, Jost S, Ritz J, Henrich TJ.

Blood Adv. 2018 Jun 26;2(12):1412-1416. doi: 10.1182/bloodadvances.2018016329. No abstract available.

7.

Targeted HIV testing at birth supported by low and predictable mother-to-child transmission risk in Botswana.

Ibrahim M, Maswabi K, Ajibola G, Moyo S, Hughes MD, Batlang O, Sakoi M, Auletta-Young C, Vaughan L, Lockman S, Jean-Philippe P, Yu X, Lichterfeld M, Kuritzkes DR, Makhema J, Shapiro RL.

J Int AIDS Soc. 2018 May;21(5):e25111. doi: 10.1002/jia2.25111.

8.

Motion-Based Immunological Detection of Zika Virus Using Pt-Nanomotors and a Cellphone.

Draz MS, Lakshminaraasimulu NK, Krishnakumar S, Battalapalli D, Vasan A, Kanakasabapathy MK, Sreeram A, Kallakuri S, Thirumalaraju P, Li Y, Hua S, Yu XG, Kuritzkes DR, Shafiee H.

ACS Nano. 2018 Jun 26;12(6):5709-5718. doi: 10.1021/acsnano.8b01515. Epub 2018 May 16.

PMID:
29767504
9.

Human Herpes Virus 8 in HIV-1 infected individuals receiving cancer chemotherapy and stem cell transplantation.

Hogan LE, Hanhauser E, Hobbs KS, Palmer CD, Robles Y, Jost S, LaCasce AS, Abramson J, Hamdan A, Marty FM, Kuritzkes DR, Henrich TJ.

PLoS One. 2018 May 10;13(5):e0197298. doi: 10.1371/journal.pone.0197298. eCollection 2018.

10.

Resistance to Dolutegravir-A Chink in the Armor?

Kuritzkes DR.

J Infect Dis. 2018 Jul 24;218(5):673-675. doi: 10.1093/infdis/jiy186. No abstract available.

11.

Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.

Strongin Z, Sharaf R, VanBelzen DJ, Jacobson JM, Connick E, Volberding P, Skiest DJ, Gandhi RT, Kuritzkes DR, O'Doherty U, Li JZ.

J Virol. 2018 May 29;92(12). pii: e00285-18. doi: 10.1128/JVI.00285-18. Print 2018 Jun 15.

12.

Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30.

Hogan LE, Vasquez J, Hobbs KS, Hanhauser E, Aguilar-Rodriguez B, Hussien R, Thanh C, Gibson EA, Carvidi AB, Smith LCB, Khan S, Trapecar M, Sanjabi S, Somsouk M, Stoddart CA, Kuritzkes DR, Deeks SG, Henrich TJ.

PLoS Pathog. 2018 Feb 22;14(2):e1006856. doi: 10.1371/journal.ppat.1006856. eCollection 2018 Feb.

13.

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption.

Park YJ, Etemad B, Ahmed H, Naranbhai V, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Carrington M, Li JZ.

Pathog Immun. 2017;2(3):431-445. doi: 10.20411/pai.v2i3.222. Epub 2017 Nov 27.

14.

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.

Phillips AN, Cambiano V, Nakagawa F, Revill P, Jordan MR, Hallett TB, Doherty M, De Luca A, Lundgren JD, Mhangara M, Apollo T, Mellors J, Nichols B, Parikh U, Pillay D, Rinke de Wit T, Sigaloff K, Havlir D, Kuritzkes DR, Pozniak A, van de Vijver D, Vitoria M, Wainberg MA, Raizes E, Bertagnolio S; Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa.

Lancet HIV. 2018 Mar;5(3):e146-e154. doi: 10.1016/S2352-3018(17)30190-X. Epub 2017 Nov 22.

15.

HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG.

PLoS Med. 2017 Nov 7;14(11):e1002417. doi: 10.1371/journal.pmed.1002417. eCollection 2017 Nov.

16.

Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV.

Belury MA, Bowman E, Gabriel J, Snyder B, Kulkarni M, Palettas M, Mo X, Lake JE, Zidar D, Sieg SF, Rodriguez B, Playford MP, Andrade A, Kuritzkes DR, Mehta NN, Lederman MM, Funderburg NT.

Pathog Immun. 2017;2(3):376-403. doi: 10.20411/pai.v2i3.218. Epub 2017 Oct 6.

17.

Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.

Godfrey C, Thigpen MC, Crawford KW, Jean-Phillippe P, Pillay D, Persaud D, Kuritzkes DR, Wainberg M, Raizes E, Fitzgibbon J.

J Infect Dis. 2017 Dec 1;216(suppl_9):S798-S800. doi: 10.1093/infdis/jix137. Review. No abstract available.

18.

Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy.

Henrich TJ, Hobbs KS, Hanhauser E, Scully E, Hogan LE, Robles YP, Leadabrand KS, Marty FM, Palmer CD, Jost S, Körner C, Li JZ, Gandhi RT, Hamdan A, Abramson J, LaCasce AS, Kuritzkes DR.

J Infect Dis. 2017 Jul 15;216(2):254-262. doi: 10.1093/infdis/jix265.

19.

Metagenomic Sequencing of an Echovirus 30 Genome From Cerebrospinal Fluid of a Patient With Aseptic Meningitis and Orchitis.

Piantadosi A, Mukerji SS, Chitneni P, Cho TA, Cosimi LA, Hung DT, Goldberg MB, Sabeti PC, Kuritzkes DR, Grad YH.

Open Forum Infect Dis. 2017 Jul 28;4(3):ofx138. doi: 10.1093/ofid/ofx138. eCollection 2017 Summer.

20.

Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.

Paredes R, Tzou PL, van Zyl G, Barrow G, Camacho R, Carmona S, Grant PM, Gupta RK, Hamers RL, Harrigan PR, Jordan MR, Kantor R, Katzenstein DA, Kuritzkes DR, Maldarelli F, Otelea D, Wallis CL, Schapiro JM, Shafer RW.

PLoS One. 2017 Jul 28;12(7):e0181357. doi: 10.1371/journal.pone.0181357. eCollection 2017.

21.

Rapid, label-free CD4 testing using a smartphone compatible device.

Kanakasabapathy MK, Pandya HJ, Draz MS, Chug MK, Sadasivam M, Kumar S, Etemad B, Yogesh V, Safavieh M, Asghar W, Li JZ, Tsibris AM, Kuritzkes DR, Shafiee H.

Lab Chip. 2017 Aug 22;17(17):2910-2919. doi: 10.1039/c7lc00273d.

22.

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.

Hill AL, Rosenbloom DIS, Goldstein E, Hanhauser E, Kuritzkes DR, Siliciano RF, Henrich TJ.

PLoS Pathog. 2017 Jul 6;13(7):e1006488. doi: 10.1371/journal.ppat.1006488. eCollection 2017 Jul.

23.

Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration.

Cardozo EF, Andrade A, Mellors JW, Kuritzkes DR, Perelson AS, Ribeiro RM.

PLoS Pathog. 2017 Jul 5;13(7):e1006478. doi: 10.1371/journal.ppat.1006478. eCollection 2017 Jul.

24.

High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay.

Yucha RW, Hobbs KS, Hanhauser E, Hogan LE, Nieves W, Ozen MO, Inci F, York V, Gibson EA, Thanh C, Shafiee H, El Assal R, Kiselinova M, Robles YP, Bae H, Leadabrand KS, Wang S, Deeks SG, Kuritzkes DR, Demirci U, Henrich TJ.

EBioMedicine. 2017 Jun;20:217-229. doi: 10.1016/j.ebiom.2017.05.006. Epub 2017 May 4.

25.

Paper microchip with a graphene-modified silver nano-composite electrode for electrical sensing of microbial pathogens.

Safavieh M, Kaul V, Khetani S, Singh A, Dhingra K, Kanakasabapathy MK, Draz MS, Memic A, Kuritzkes DR, Shafiee H.

Nanoscale. 2017 Feb 2;9(5):1852-1861. doi: 10.1039/c6nr06417e.

26.

A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?

Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC.

Pathog Immun. 2016 Spring;1(1):154-164.

27.

Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity.

Funderburg NT, Xu D, Playford MP, Joshi AA, Andrade A, Kuritzkes DR, Lederman MM, Mehta NN.

Antivir Ther. 2017;22(1):71-75. doi: 10.3851/IMP3091. Epub 2016 Oct 14.

28.

Humoral Immune Pressure Selects for HIV-1 CXC-chemokine Receptor 4-using Variants.

Lin N, Gonzalez OA, Registre L, Becerril C, Etemad B, Lu H, Wu X, Lockman S, Essex M, Moyo S, Kuritzkes DR, Sagar M.

EBioMedicine. 2016 Jun;8:237-247. doi: 10.1016/j.ebiom.2016.04.040. Epub 2016 May 5.

29.

Why cure, why now?

Kuritzkes DR.

J Med Ethics. 2017 Feb;43(2):67-70. doi: 10.1136/medethics-2015-103113. Epub 2016 Jun 7.

30.

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.

Hill AL, Rosenbloom DI, Goldstein E, Hanhauser E, Kuritzkes DR, Siliciano RF, Henrich TJ.

PLoS Pathog. 2016 Apr 27;12(4):e1005535. doi: 10.1371/journal.ppat.1005535. eCollection 2016 Apr. Erratum in: PLoS Pathog. 2016 Jul;12(7):e1005778. PLoS Pathog. 2017 Jul 6;13(7):e1006488.

31.

HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States.

Landovitz RJ, Tran TT, Cohn SE, Ofotokun I, Godfrey C, Kuritzkes DR, Lennox JL, Currier JS, Ribaudo HJ.

AIDS Behav. 2016 Dec;20(12):2983-2995.

32.

Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.

Treasure GC, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Li JZ.

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):310-3. doi: 10.1097/QAI.0000000000000964.

33.

Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.

Casadellà M, Noguera-Julian M, Sunpath H, Gordon M, Rodriguez C, Parera M, Kuritzkes DR, Marconi VC, Paredes R.

AIDS. 2016 Apr 24;30(7):1137-40. doi: 10.1097/QAD.0000000000001033.

34.

Hematopoietic stem cell transplantation for HIV cure.

Kuritzkes DR.

J Clin Invest. 2016 Feb;126(2):432-7. doi: 10.1172/JCI80563. Epub 2016 Jan 5. Review.

35.

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.

Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT.

AIDS. 2016 Jan 28;30(3):343-53. doi: 10.1097/QAD.0000000000000953. Erratum in: AIDS. 2016 Sep 10;30(14):2259.

36.

Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).

Andrade A, Guedj J, Rosenkranz SL, Lu D, Mellors J, Kuritzkes DR, Perelson AS, Ribeiro RM; ACTG A5249s protocol team.

AIDS. 2015 Nov 28;29(18):2419-26. doi: 10.1097/QAD.0000000000000843.

37.

CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.

Henrich TJ, Hanhauser E, Harrison LJ, Palmer CD, Romero-Tejeda M, Jost S, Bosch RJ, Kuritzkes DR.

J Infect Dis. 2016 Mar 1;213(5):766-70. doi: 10.1093/infdis/jiv504. Epub 2015 Oct 28.

38.

Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1-Infected Men.

Scully E, Lockhart A, Huang L, Robles Y, Becerril C, Romero-Tejeda M, Albrecht MA, Palmer CD, Bosch RJ, Altfeld M, Kuritzkes DR, Lin NH.

J Infect Dis. 2016 Mar 1;213(5):771-5. doi: 10.1093/infdis/jiv501. Epub 2015 Oct 22.

39.

Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy.

McCausland MR, Juchnowski SM, Zidar DA, Kuritzkes DR, Andrade A, Sieg SF, Lederman MM, Funderburg NT.

PLoS One. 2015 Oct 2;10(10):e0139474. doi: 10.1371/journal.pone.0139474. eCollection 2015.

40.

Multitarget, quantitative nanoplasmonic electrical field-enhanced resonating device (NE2RD) for diagnostics.

Inci F, Filippini C, Baday M, Ozen MO, Calamak S, Durmus NG, Wang S, Hanhauser E, Hobbs KS, Juillard F, Kuang PP, Vetter ML, Carocci M, Yamamoto HS, Takagi Y, Yildiz UH, Akin D, Wesemann DR, Singhal A, Yang PL, Nibert ML, Fichorova RN, Lau DT, Henrich TJ, Kaye KM, Schachter SC, Kuritzkes DR, Steinmetz LM, Gambhir SS, Davis RW, Demirci U.

Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4354-63. doi: 10.1073/pnas.1510824112. Epub 2015 Jul 20.

41.

Printed Flexible Plastic Microchip for Viral Load Measurement through Quantitative Detection of Viruses in Plasma and Saliva.

Shafiee H, Kanakasabapathy MK, Juillard F, Keser M, Sadasivam M, Yuksekkaya M, Hanhauser E, Henrich TJ, Kuritzkes DR, Kaye KM, Demirci U.

Sci Rep. 2015 Jun 5;5:9919. doi: 10.1038/srep09919.

42.

Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics.

Li JZ, Arnold KB, Lo J, Dugast AS, Plants J, Ribaudo HJ, Cesa K, Heisey A, Kuritzkes DR, Lauffenburger DA, Alter G, Landay A, Grinspoon S, Pereyra F.

Open Forum Infect Dis. 2015 Jan 13;2(1):ofu117. doi: 10.1093/ofid/ofu117. eCollection 2015 Jan.

43.

Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.

Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS; AIDS Clinical Trials Group (ACTG) A5257 Team.

Clin Infect Dis. 2015 Jun 15;60(12):1842-51. doi: 10.1093/cid/civ193. Epub 2015 Mar 12.

44.

Paper and flexible substrates as materials for biosensing platforms to detect multiple biotargets.

Shafiee H, Asghar W, Inci F, Yuksekkaya M, Jahangir M, Zhang MH, Durmus NG, Gurkan UA, Kuritzkes DR, Demirci U.

Sci Rep. 2015 Mar 6;5:8719. doi: 10.1038/srep08719.

45.

Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study.

Henrich TJ, McLaren PJ, Rao SS, Lin NH, Hanhauser E, Giguel F, Gulick RM, Ribaudo H, de Bakker PI, Kuritzkes DR.

Open Forum Infect Dis. 2014 May 22;1(1):ofu018. doi: 10.1093/ofid/ofu018. eCollection 2014 Mar.

46.

Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.

Henrich TJ, Hanhauser E, Hu Z, Stellbrink HJ, Noah C, Martin JN, Deeks SG, Kuritzkes DR, Pereyra F.

AIDS. 2015 May 15;29(8):867-76. doi: 10.1097/QAD.0000000000000629.

47.

Patients infected with CRF07_BC have significantly lower viral loads than patients with HIV-1 subtype B: mechanism and impact on disease progression.

Huang SW, Wang SF, Lin YT, Yen CH, Lee CH, Wong WW, Tsai HC, Yang CJ, Hu BS, Lin YH, Wang CT, Wang JJ, Hu Z, Kuritzkes DR, Chen YH, Chen YM.

PLoS One. 2014 Dec 11;9(12):e114441. doi: 10.1371/journal.pone.0114441. eCollection 2014.

48.

Emerging technologies for point-of-care management of HIV infection.

Shafiee H, Wang S, Inci F, Toy M, Henrich TJ, Kuritzkes DR, Demirci U.

Annu Rev Med. 2015;66:387-405. doi: 10.1146/annurev-med-092112-143017. Epub 2014 Nov 12. Review.

PMID:
25423597
49.

Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):I-22. doi: 10.7326/P14-9035. No abstract available.

PMID:
25285557
50.

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum in: Ann Intern Med. 2014 Nov 4;161(9):680.

Supplemental Content

Loading ...
Support Center